TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

Fadi Azar; Jules Deforges; Christelle Demeusoit; Patricia Kleinpeter; Christelle Remy; Nathalie Silvestre; Johann Foloppe; Laetitia Fend; Clémentine Spring-Giusti; Eric Quéméneur; Jean-Baptiste Marchand

doi:10.1136/jitc-2024-009302

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF

PDF +
Supplementary
Material

Oncolytic and local immunotherapy

Original research

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

	Abstract	Full	Pdf
Jul 2024	348	352	148
Aug 2024	372	373	541
Total	720	725	689

Main menu

Online download statistics by month:

Online download statistics by month: July 2024 to August 2024

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: July 2024 to August 2024

Read the full text or download the PDF:

Log in using your username and password